Cantor Fitzgerald Maintains Overweight on Abeona Therapeutics, Raises Price Target to $30

Cantor Fitzgerald analyst Kristen Kluska has maintained an Overweight rating on Abeona Therapeutics (NASDAQ: ABEO) and raised the price target from $28 to $30. This adjustment reflects a positive outlook for the company's performance in the market.